TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31869417

Group type: EXPERIMENTAL
Intervention: Donor and host HLA both expressed ligands for donor inhibitory KIRs
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: NK cells expressing 3 inhibitory receptors (KIR2DL1/2DL3/3DL1)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Donor and host HLA both expressed all ligands for donor inhibitory KIRs
Number of subjects: 390
Study: 31870231

Group type: EXPERIMENTAL
Intervention: High ordering cardiologists (top tertile of rA transthoracic echocardiogram ordering frequency)
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Low ordering cardiologists (bottom tertile of rA transthoracic echocardiogram ordering frequency)
Number of subjects: 1677
Study: 31870336

Group type: EXPERIMENTAL
Intervention: Habitual sleep assessment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Obesity risk behaviors assessment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Data collection over two years (8, 16, and 24 months after Time 1)
Number of subjects: 300
Study: 31870369

Group type: EXPERIMENTAL
Intervention: CHU9D-DK (using UK adult algorithm)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: CHU9D-DK (using Australian adolescent algorithm)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: PedsQL
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: CHU9D-DK
Number of subjects: 272
Study: 31870408

Group type: EXPERIMENTAL
Intervention: Transport physical activity (PA)
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Leisure physical activity (PA)
Number of subjects: 9218

Group type: COMPARATOR
Intervention: Transport PA by sex
Number of subjects: 9218

Group type: COMPARATOR
Intervention: Leisure PA by sex
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Prevalence of not meeting PA recommendations for transport
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Prevalence of not meeting PA recommendations for leisure
Number of subjects: 9218

Group type: COMPARATOR
Intervention: Sitting time by demographic factors
Number of subjects: 9218
Study: 31870462

Group type: EXPERIMENTAL
Intervention: Teacher-reported internalizing symptoms
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Children's self-reported depressive symptoms
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Children's self-reported symptoms of anxiety
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Teacher-rated internalizing symptoms
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Children's self-reported symptoms of depression
Number of subjects: 750
Study: 31870461

Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Number of subjects: 739
Study: 31870689

Group type: EXPERIMENTAL
Intervention: F/B-EVAR with multistaged approach
Number of subjects: 80
Study: 31870883

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years
Number of subjects: 83
Study: 31870951

Group type: EXPERIMENTAL
Intervention: ECA-MRI
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HBA-MRI
Number of subjects: 171
Study: 31871217

Group type: EXPERIMENTAL
Intervention: Periconceptional folate
Number of subjects: 311
Study: 31871448

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 91
Study: 31871455

Group type: EXPERIMENTAL
Intervention: Tailored nutrition and lifestyle intervention (6-month intervention with group education, cooking demonstrations, motivational interviewing, online resources)
Number of subjects: 29
Study: 31871784

Group type: EXPERIMENTAL
Intervention: Parental exposure to stressors related to community safety
Number of subjects: 273
Study: 31871787

Group type: EXPERIMENTAL
Intervention: Lutein and Zeaxanthin supplementation for one year
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31872062

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study: 31872152

Group type: EXPERIMENTAL
Intervention: Family economic strengthening (matched savings accounts, financial management training, small business development)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Bolstered usual care (SOC) (enhanced adherence sessions)
Number of subjects: 702
Study: 31872157

Group type: EXPERIMENTAL
Intervention: Integrated primary care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (behavioral health only)
Number of subjects: 0
Study: 31872324

Group type: EXPERIMENTAL
Intervention: Dual-tracer PET/CT imaging
Number of subjects: 31
Study: 31872928

Group type: EXPERIMENTAL
Intervention: Single-agent pazopanib at a dose of 800 mg daily
Number of subjects: 34
Study: 31874051

Group type: EXPERIMENTAL
Intervention: Uncontrolled severe asthma (SA)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Controlled severe asthma (SA)
Number of subjects: 670
Study: 31874111

Group type: EXPERIMENTAL
Intervention: Elevated interferon signature (IRG-S)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Neutrophilic panniculitis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Basal ganglia calcifications
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interstitial lung disease
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Myositis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LRBA mutations
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IKBKG splice variants
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: SAMD9L mutations
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mutations in SAMHD1, TREX1, PSMB8, or PSMG2
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Anti-MDA5 autoantibody-positive juvenile dermatomyositis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Unclassified patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IRG-S
Number of subjects: 66
Study: 31874154

Group type: EXPERIMENTAL
Intervention: Questionnaire at 1 week and at 1, 3, 6, and 12 months after injury
Number of subjects: 4239
Study: 31874588

Group type: EXPERIMENTAL
Intervention: Latent class analysis of family social environment typologies
Number of subjects: 0
Study: 31874901

Group type: EXPERIMENTAL
Intervention: Selective histopathological examination based on macroscopic assessment by the surgeon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine histopathological examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost analysis of selective histopathological examination
Number of subjects: 0
Study: 31874899

Group type: COMPARATOR
Intervention: SDMs who were not approached for organ donation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SDMs who were approached and consented to donate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SDMs who were approached but did not consent to donate
Number of subjects: 60
Study: 31875196

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d for 14 weeks
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study: 31875881

Group type: EXPERIMENTAL
Intervention: Multi-modal density testing (MMDT) framework applied to MRI data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMDT framework
Number of subjects: 0
Study: 31875915

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) for 16 weeks
Number of subjects: 106
Study: 31875931

Group type: EXPERIMENTAL
Intervention: Dotinurad 2 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dotinurad 4 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study: 31876107

Group type: EXPERIMENTAL
Intervention: Sirolimus combined with oral metronomic therapy (twice daily celecoxib, alternating etoposide and cyclophosphamide every three weeks)
Number of subjects: 18
Study: 31876124

Group type: EXPERIMENTAL
Intervention: Electrical impedance myography (EIM) at 100 kHz resistance in ambulatory boys
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Electrical impedance myography (EIM) at 100 kHz resistance in non-ambulatory boys
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: EIM 100 kHz resistance values
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: EIM
Number of subjects: 44
Study: 31876911

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily for a median of 41 months (range 0.2-58 months)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily
Number of subjects: 134
Study: 31876927

Group type: EXPERIMENTAL
Intervention: Coronary sinus neuropeptide Y (CS NPY) levels ≥ 130 pg/mL
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (organ donors)
Number of subjects: 105
Study: 31877507

Group type: EXPERIMENTAL
Intervention: Attendance at in-laboratory polysomnography (iPSG)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Model 1 (demographic, lifestyle, and cognitive status)
Number of subjects: 122
Study: 31878890

Group type: EXPERIMENTAL
Intervention: Complete BA configuration
Number of subjects: 34

Group type: COMPARATOR
Intervention: Incomplete BA configuration
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Proximal BA configuration
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Distal BA configuration
Number of subjects: 34
Study: 31878895

Group type: EXPERIMENTAL
Intervention: Zika virus infection in pregnant women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zika virus infection in children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zika virus infection in symptomatic rash/fever illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zika virus infection
Number of subjects: 0
Study: 31878938

Group type: EXPERIMENTAL
Intervention: PD-L1 high (≥ 25% TC)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: PD-L1 ≥ 10% TC
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: PD-L1 ≥ 50% TC
Number of subjects: 412
Study: 31879324

Group type: EXPERIMENTAL
Intervention: T-Track® CMV (cytomegalovirus-specific cellular immunity measured using a standardized IFN-γ ELISpot assay)
Number of subjects: 175
Study: 31879328

Group type: EXPERIMENTAL
Intervention: Flow cytometry positivity for occult central nervous system disease
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Central nervous system disease negative status
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Status of manifest and occult central nervous system disease positivity
Number of subjects: 240
Study: 31879782

Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg
Number of subjects: 109
Study: 31879814

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 9
Study: 31879838

Group type: EXPERIMENTAL
Intervention: General population after ICH episode
Number of subjects: 3594

Group type: COMPARATOR
Intervention: Complex chronic patients after ICH episode
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: Age > 80 years
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 3594

Group type: COMPARATOR
Intervention: General population
Number of subjects: 3594

Group type: COMPARATOR
Intervention: Complex chronic patients
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: Internal validation of the model
Number of subjects: 3594

Group type: COMPARATOR
Intervention: External validation in complex chronic patients
Number of subjects: 3594
Study: 31879842

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg/28 days
Number of subjects: 0
Study: 31880308

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 15846

Group type: COMPARATOR
Intervention: Other bDMARDs
Number of subjects: 15846
Study: 31880806

Group type: EXPERIMENTAL
Intervention: Cochlear implants (CIs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal hearing control group
Number of subjects: 10
Study: 31880950

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 44
Study: 31881608

Group type: EXPERIMENTAL
Intervention: Ultrasound surveillance (Doppler ultrasound)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sequential compression devices
Number of subjects: 1000
Study: 31881616

Group type: EXPERIMENTAL
Intervention: Enzymatic digestion combined with mechanical distortion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enzymatic digestion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mechanical distortion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Excised adipose tissue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirated adipose tissue
Number of subjects: 20
Study: 31881853

Group type: EXPERIMENTAL
Intervention: Trametinib (daily oral at full dose for 18 cycles of 28 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 150
Study: 31882011

Group type: EXPERIMENTAL
Intervention: Professional's subjective feelings and clinical judgment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Medical history
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Juvenile Fibromyalgia (JFM) concept
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Non-organic criteria for diagnosis
Number of subjects: 25
Study: 31882281

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (3 cycles)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: mpMRI assessment
Number of subjects: 82
Study: 31882377

Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T cells with CD28 co-stimulatory domain
Number of subjects: 5
Study: 31883202

Group type: EXPERIMENTAL
Intervention: Genetic cancer risk assessment (GCRA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interventions to reduce disparities in GCRA uptake
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Targeted interventions
Number of subjects: 20
Study: 31883396

Group type: EXPERIMENTAL
Intervention: Ibrutinib combined with bortezomib and dexamethasone
Number of subjects: 76
Study: 31883529

Group type: EXPERIMENTAL
Intervention: Microglia from mucolipidosis type IV
Number of subjects: 2

Group type: COMPARATOR
Intervention: Microglia from Fabry disease mice
Number of subjects: 2
Study: 31883679

Group type: EXPERIMENTAL
Intervention: High platelet FcγRIIa expression (>11,000/platelet) in patients identified as high risk by the GRACE score
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: High platelet FcγRIIa expression (>11,000/platelet) in patients identified as high risk by the DAPT score
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: High platelet FcγRIIa expression
Number of subjects: 197
Study: 31883966

Group type: EXPERIMENTAL
Intervention: Anxiety manipulation (threat-of-shock)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fear (not explicitly manipulated in this study)
Number of subjects: 0
Study: 31884564

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 6 µg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 10 µg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 15 µg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 20 µg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Topical bimatoprost 0.03% (Control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overall study eyes (all doses combined)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 75
Study: 31884676

Group type: EXPERIMENTAL
Intervention: GSK's IIV4 (one dose)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: GSK's IIV4 (second dose)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: GSK's IIV4
Number of subjects: 1060
Study: 31885047

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation for IVF/ICSI in patients with isthmocele
Number of subjects: 103

Group type: COMPARATOR
Intervention: Ovarian stimulation for IVF/ICSI in patients without isthmocele
Number of subjects: 103
Study: 31885349

Group type: EXPERIMENTAL
Intervention: Erlotinib (N-TKI group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chemotherapy (N-chemo group)
Number of subjects: 31
Study: 31885697

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31885750

Group type: EXPERIMENTAL
Intervention: 100 mg mepolizumab (subcutaneous)
Number of subjects: 9
Study: 31885756

Group type: EXPERIMENTAL
Intervention: sEMG recording of temporalis and masseters
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sEMG recording of temporalis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sEMG combined with clinical evaluation
Number of subjects: 50
Study: 31885895

Group type: EXPERIMENTAL
Intervention: Ultrasonic deep lateral wall bony decompression with partial rim sparing (DLW-PRS) using SONOPET® ultrasonic aspirator.
Number of subjects: 35
Study: 31886028

Group type: EXPERIMENTAL
Intervention: M-MIST and PRF
Number of subjects: 36

Group type: COMPARATOR
Intervention: M-MIST alone
Number of subjects: 36
Study: 31886253

Group type: EXPERIMENTAL
Intervention: Selenium + ischemia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Melatonin + ischemia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Selenium + Melatonin + ischemia
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ischemia group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 31886877

Group type: EXPERIMENTAL
Intervention: Uterine lavage procedure
Number of subjects: 81

Group type: COMPARATOR
Intervention: IVF control cycle
Number of subjects: 81
Study: 31887145

Group type: EXPERIMENTAL
Intervention: PNNS-GS2 (Programme National Nutrition Santé Guidelines Score 2)
Number of subjects: 54089
Study: 31887274

Group type: EXPERIMENTAL
Intervention: En bloc EMR (e-EMR)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Piecemeal EMR (p-EMR)
Number of subjects: 570
Study: 31887431

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg qd)
Number of subjects: 22
Study: 31887443

Group type: EXPERIMENTAL
Intervention: NAFLD
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: FIB-4 scores greater than 2.67
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: NFS scores greater than 0.676
Number of subjects: 898
Study: 31888507

Group type: EXPERIMENTAL
Intervention: RF-SLAM (random forest for SLAM data analysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of preceding heart failure hospitalizations
Number of subjects: 0
Study: 31888588

Group type: EXPERIMENTAL
Intervention: Multisensory waiting room (lighting column, rhythmic music)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional waiting room
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer waiting time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visit purpose (dental examination or treatment with conscious sedation)
Number of subjects: 0
Study: 31888643

Group type: EXPERIMENTAL
Intervention: Asymptomatic P. falciparum monoinfection
Number of subjects: 16959

Group type: EXPERIMENTAL
Intervention: Asymptomatic P. vivax monoinfection
Number of subjects: 16959

Group type: COMPARATOR
Intervention: No Plasmodium detected initially
Number of subjects: 16959
Study: 31888672

Group type: EXPERIMENTAL
Intervention: Matched therapy
Number of subjects: 3487

Group type: COMPARATOR
Intervention: Unmatched therapy
Number of subjects: 3487
Study: 31888703

Group type: EXPERIMENTAL
Intervention: rs10865710 polymorphism
Number of subjects: 1131
Study: 31888721

Group type: EXPERIMENTAL
Intervention: Non-pulsatile perfusion
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hypocapnia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MCAv/PaCO2 relationship
Number of subjects: 32
Study: 31888931

Group type: EXPERIMENTAL
Intervention: Confirmed IMD cases (15-24 years 11 months at time of disease)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control participants (17-34 years 11 months)
Number of subjects: 128
Study: 31888941

Group type: EXPERIMENTAL
Intervention: Web-based decision aid and planning tool for family-building after cancer (accessed post-baseline survey)
Number of subjects: 100
Study: 31889230

Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg (single oral administration)
Number of subjects: 12
Study: 31889307

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 12-16 sessions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cingulo-opercular structural connections
Number of subjects: 28
Study: 31890041

Group type: EXPERIMENTAL
Intervention: EVO 2.5 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: EVO 5 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: EVO 10 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: SITA 100 mg
Number of subjects: 146
Study: 31890043

Group type: EXPERIMENTAL
Intervention: 12-months exercise program (a combination of aerobic and strength training for a minimum of 150 min per week)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 137
Study: 31890160

Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam (CAZ-AVI) plus metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftolozane/tazobactam plus metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study: 31890195

Group type: EXPERIMENTAL
Intervention: Diathermy (Hot group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Knife excision (Cold group)
Number of subjects: 29
Study: 31890261

Group type: EXPERIMENTAL
Intervention: CCAs (Collaborative Care Approaches) used by adolescents to inform their S.M.A.R.T. goals over a 3-week period
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (control group) where adolescents set S.M.A.R.T. goals without CCAs
Number of subjects: 50
Study: 31890266

Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention (4 weekly aerobic and strength training sessions)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 16
Study: 31890631

Group type: EXPERIMENTAL
Intervention: Inappropriate passwords for intervention access
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grade-8 reading level passwords for intervention access
Number of subjects: 0
Study: 31890850

Group type: EXPERIMENTAL
Intervention: Radio programme plus community engagement (LDGs, street theatre, local leader messaging)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Radio programming alone
Number of subjects: 1440
Study: 31890902

Group type: EXPERIMENTAL
Intervention: V7 TB vaccine (10 µg of hydrolyzed heat-killed mycobacteria)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0